Daniele Buetti

Lionize Raises $3 Million Seed Round in Deal with Cultivation Capital and ScOp Venture Capital

Retrieved on: 
Friday, September 9, 2022
Software, Digital Marketing, Social Media, Marketing, Artificial Intelligence, Communications, Technology, Influencer, Software, Scop, Artificial intelligence, DoubleClick, Daniele Buetti, Investment, Software as a service, ROI, Industry, Marketing, SoulCycle, Efficiency, Public relations, Lionize

Lionize, a SaaS leader in the influencer marketing industry, announced today that it has secured a $3 million Series Seed investment led by St. Louis-based Cultivation Capital, with participation by ScOp Venture Capital, a Santa Barbara-based firm managed by DoubleClick founder Kevin OConnor.

Key Points: 
  • Lionize, a SaaS leader in the influencer marketing industry, announced today that it has secured a $3 million Series Seed investment led by St. Louis-based Cultivation Capital, with participation by ScOp Venture Capital, a Santa Barbara-based firm managed by DoubleClick founder Kevin OConnor.
  • Lionize is the brainchild of co-founders Chris Buetti, Ben Devore, and Austin Rosenthal, who were previously running a traditional marketing agency.
  • We are deeply grateful for Cultivation Capital and ScOp Venture Capitals investments, said CEO Chris Buetti.
  • Cultivation Capital is an early-stage venture capital firm investing in software technology, life sciences, agriculture technology, and geospatial technology companies.

Teleflex awarded Central Venous Access contract from Vizient

Retrieved on: 
Monday, August 1, 2022
Blood vessel, Urology, Silver sulfadiazine, American Journal of Infection Control, Security (finance), NP, ME, Infection Control & Hospital Epidemiology, Central venous catheter, Infection, American Journal, U.S. Securities and Exchange Commission, Tracheotomy, Fungus, CLABSI, Solution, CVC, TFX, Teleflex, Radiology, Chlorhexidine, Central, GLOBE, Health, General manager, Thrombosis, Comparison, GA, Hypersensitivity, Annual report, Daniele Buetti, Anesthesia, Weck, LMA, Bloodstream infections, Centers for Disease Control and Prevention, NYSE, Risk, YZ, Burns, Gram-negative bacteria, Patient, CFR, Prostatic urethral lift, Center, Emergency medicine, Medical device, Medical imaging, Health insurance, Birth control, Wood drying, Pharmaceutical industry, Arrow, QuikClot, Vizient, Inc., Frederick B. Deknatel

WAYNE, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has been awarded a contract for the supply of Central Venous Access products from Vizient, Inc., the nations largest member-driven healthcare performance improvement company.

Key Points: 
  • WAYNE, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has been awarded a contract for the supply of Central Venous Access products from Vizient, Inc., the nations largest member-driven healthcare performance improvement company.
  • This new agreement allows Vizient members to take advantage of special pricing and terms pre-negotiated by Vizient for Central Venous Access products.
  • As the market leader in Central Venous Catheters (CVCs)1, we are pleased to offer Vizient members one of the broadest portfolios of central access products available, said Lisa Kudlacz, President and General Manager, Teleflex Vascular.
  • The group purchasing agreement includes access to Teleflex Arrowg+ard Blue Plus CVCs and Arrow ErgoPack Complete Systems.